miércoles, 7 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· May 19, 2026

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

View original at finance.yahoo.com

“lifted cash to $18.2B at year-end 2025 from $3.3B a year earlier.”

Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

SoFi Q1 2026 net income increased 134% year-over-year to $166.7 million
60% confidence
Pfizer's non-COVID portfolio achieved 9% operational revenue growth
60% confidence
Pfizer faces a $1.5 billion revenue headwind in 2026 from loss of drug exclusivity and Most Favored Nation drug pricing pressure
60% confidence
AT&T grew its cash position from $3.3 billion at year-end 2024 to $18.2 billion at year-end 2025
60% confidence
SoFi Q1 2026 loan originations reached a record $12.18 billion, up 68% year-over-year
60% confidence
AT&T's converged connectivity and growing free cash flow makes the dividend durable
60% confidence
AT&T Q1 2026 adjusted EPS grew 11.8% year-over-year to $0.57
60% confidence
Equity markets are trading at elevated multiples in May 2026
60% confidence
AT&T legacy wireline revenue declined more than 20% in 2026
60% confidence
Analyst consensus target price for Pfizer is $29.19
60% confidence
Analyst target price for SoFi Technologies is $21.10
60% confidence
Analyst target price for AT&T is $30.37
60% confidence

Data points we hold from this source

AT&T Inc. · debt	173.99 USD
AT&T Inc. · analyst target price	30.37 USD
AT&T Inc. · forward pe	11 multiple

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,986

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados

Consulta estos datos → isubstrate.com

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look — Source | Via News | es.VIA.NEWS